Back to results
US 2011/0212468 A1Published application
Biomarkers and methods for determining disease progression in nonalcoholic steatohepatitis (nash)
AssigneeChildren's Hospital Medical Center
InventorsRohit Kohli, Stavra A. Xanthakos, Michael V. Miles
Life of this patent
Estimating the term…
Abstract
Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.
Claims47
A method of determining the presence of fatty liver disease (FLD) in a patient, comprising:
- providing a sample from a patient;
- measuring the level of coenzyme Q (CoQ) in the sample;
- and
- comparing the CoQ value from the patient with a threshold value, wherein if the CoQ value meets the threshold value the patient is determined to be at risk for fatty liver disease.
1 more element
Dependencies are inferred from the claim text.